Market Place
Sourcing Support
Grants From Centro Para El Desarrollo Tecnológico Y La Innovación
18 Jun 2024 //
PRESS RELEASE
Glenmark partners with Pfizer to launch abrocitinib in India
31 Jan 2024 //
ECONOMIC TIMES
FDA Approves Pfizer`s Supplemental New Drug Application for CIBINQO
10 Feb 2023 //
BUSINESSWIRE
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
EMA backs restrictions on certain immune-regulating drugs
12 Nov 2022 //
BIOPHARMADIVE
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
01 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns
29 Oct 2022 //
ENDPTS
NICE recommend’s use of Leo Pharma’s Adtralza
07 Jul 2022 //
PHARMATIMES
Health Canada Approves Use of CIBINQO for Moderate-to-Severe Atopic Dermatitis
04 Jul 2022 //
BIOSPACE
NICE recommends dermatitis treatment for use in NHS England and Wales
30 Jun 2022 //
PHARMAFILE
FDA offers a tardy green light to Pfizer`s JAK1 drug abrocitinib
15 Jan 2022 //
ENDPTS
European Commission approves Pfizer drug for adults moderate-dermatitis
14 Dec 2021 //
PHARMAFILE
European Commission approves Pfizer’s atopic dermatitis treatment
13 Dec 2021 //
PHARMATIMES
EC Approves Pfizer’s Cibinqo for Moderate-to-Severe Atopic Dermatitis
10 Dec 2021 //
BUSINESSWIRE
Pfizer`s Cibinqo (Abrocitinib) Receives Approval in Europe
09 Dec 2021 //
EMA
Japan’s MHLW Approves Pfizer’s abrocitinib for Adults and Adolescents
30 Sep 2021 //
BUSINESSWIRE
MHRA approves Pfizer’s Cibinqo to treat moderate to severe atopic dermatitis
13 Sep 2021 //
PHARMABIZ
MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO for Atopic Dermatitis
09 Sep 2021 //
BUSINESSWIRE
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial
30 Aug 2021 //
BUSINESSWIRE
FDA delays Pfizer`s Xeljanz expansion—again—on safety concerns
22 Jul 2021 //
FIERCEPHARMA
Patients gain early access to Pfizer`s atopic dermatitis drug
02 Feb 2021 //
PHARMATIMES
Pfizer Files Abrocitinib in Japan; 3rd Oral JAK Inhibitor for Atopic Dermatitis
10 Dec 2020 //
JIHO
Pfizer, still chasing Dupixent, releases fifth round of data abrocitinib
12 Nov 2020 //
ENDPTS
FDA GRANTS PRIORITY REVIEW AND EMA ACCEPTS REGULATORY FOR PFIZER’S ABROCITINIB
27 Oct 2020 //
PRESS RELEASE
FDA Grants Priority Review and EMA Accepts Regulatory for Pfizer’s Abrocitinib
27 Oct 2020 //
BUSINESSWIRE
Pfizer tips pipeline to add $15B to sales in coming years
16 Sep 2020 //
FIERCE BIOTECH
Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib
09 Jun 2020 //
BUSINESSWIRE
Safety issues for Pfizer`s Dupixent rival may hamper uptake
05 Jun 2020 //
FIERCE BIOTECH
Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published
03 Jun 2020 //
BUSINESSWIRE
Pfizer’s abrocitinib hits endpoints in late-stage atopic dermatitis study
18 Mar 2020 //
PHARMATIMES
